A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490
This study is recruiting at 14 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Multiple Sclerosis Spasticity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Celgene
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Alabama Neurology Associates · Birmingham, AL
Arizona · 1
- Perseverance Research Center,LLC · Scottsdale, AZ
Florida · 2
- Aqualane Clinical Research · Naples, FL
- USF Health · Tampa, FL
Kansas · 1
- University of Kansas Medical Center · Kansas City, KS
Massachusetts · 1
- Neurology Center of New England · Foxborough, MA
Michigan · 1
- Northwest Neurology · Southfield, MI
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Ohio · 2
- University of Cincinnati Medical Center · Cincinnati, OH
- Riverside Methodist Hospital · Columbus, OH
Pennsylvania · 1
- Thomas Jefferson University, Jefferson Headache Center · Philadelphia, PA
Tennessee · 1
- Hope Neurology · Knoxville, TN
Texas · 1
- Prime Clinical Research · Lewisville, TX
Washington · 1
- EvergreenHealth Medical Center · Kirkland, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.